Image
☰

Welcome to
Tutela Pharmaceuticals

Tutela Pharmaceuticals Inc. is a new nonprofit 501(c)(3) organization targeting the provision of single-source marketed pharmaceuticals that are subject to discontinuation or divestiture by their manufacturers. Our mission is to ensure continued and affordable access of single-source medications to patients.

Learn More alt

Collaborators

Image

A nonprofit 501(c)(3) pharmaceutical company focused on assuring access and affordabiltiy for patients.

Image

Pharma companies

Image

Distributors and
Specialty Pharmacy

Image

Patient Advocacy
Groups

View All Image

PRODUCTS

Image

A nonprofit 501(c)(3) pharmaceutical company focused on assuring access and affordabiltiy for patients.

Image
Image
Image
Image
View All Image

News

Image

GAO to research non-profit pharmaceutical companies and make recommendations to address future drug shortages.

Tutela is pleased to share the announcement from the GAO committing to further research the non-profit pharmaceutical drug manufacturing sector, and specifically make recommendations to mitigate future drug shortages. See Sec. 32017 of HR 2617, Consolidated Appropriations Act, 2023 that recently became law.

Image

Tutela is seeking a partner for advancing FK1706 in vivo studies for SARS-CoV-2. This host-targeted molecule has shown in-vitro synergy with remdesivir.

https://www.biorxiv.org/content/10.1101/2022.02.03.479080v2

Image

Tutela Pharmaceuticals Inc. has executed an Exclusive License Agreement with Astellas Pharma Inc. for worldwide rights to FK1706, an FKBP (FK506 binding protein) ligand, for the treatment, prevention, or palliation of any human diseases or disorders. This license will allow Tutela to expedite the development of FK1706 for treatment of coronavirus infections in combination with virus-targeted antivirals. Astellas had previously studied the use of FK1706 in clinical trials for the potential treatment of neuropathy.

Contact